The CDC recently updated RSV vaccine recommendations to include certain adults aged 50 and up. When is the best time to get ...

The COVID booster currently available is based on the JN.1 subvariant. Nimbus is a direct descendant of JN.1 – as is another ...

A new UK study shows that vaccinating pregnant women against RSV has led to a staggering 72% drop in hospitalizations of newborns with severe lung infections. By passing virus-fighting antibodies to ...

Respiratory Syncytial Virus (RSV) is a major cause of acute respiratory tract infections (ARTIs) and can trigger outbreaks in vulnerable settings such as nursing homes, pediatric wards, and neonatal ...

Background Respiratory syncytial virus (RSV) remains the leading cause of serious viral bronchiolitis and pneumonia in infants and young children throughout the world. The burden of disease is ...

Background: Respiratory syncytial virus (RSV) is a leading cause of severe lower respiratory infections in children, yet biomarkers for assessing disease severity remain limited. Herein, we ...

About RSV Respiratory syncytial virus (RSV) is a contagious virus that causes widespread seasonal infections and can lead to serious respiratory conditions such as bronchiolitis and pneumonia.

About ENFLONSIA™ (clesrovimab-cfor) ENFLONSIA is Merck’s extended half-life monoclonal antibody (mAb) indicated for passive immunization for the prevention of respiratory syncytial virus (RSV) lower ...